 |
|
|
| |
Efficacy and Safety of Doravirine/Islatravir (100/0.25 mg) in Adults with HIV and Renal Impairment
|
| |
| |
CROI 2026 Denver Feb 23-26
Frank Post, MD1; Princy Kumar, MD2; Chloe Orkin, MD3; Amy Colson, MD, MPH4; Moti N. Ramgopal, MD5; Alexandra Calmy, MD, PhD6; Hiroyuki Gatanaga, MD7; Jonathan Underwood, MBBS, PhD8; Stephanie O. Klopfer, PhD9; Anjana Grandhi, PhD9; Ciaran J. McMullan, MB, BCh, BAO (Hon), MMSc9; Matthew G. Johnson, MD9; Jason Y. Kim, MD, MSCE9; Rima Lahoulou, MD9; Michelle C. Fox, MD9
1King’s College Hospital NHS Foundation Trust, London, UK; 2Division of Infectious Diseases, Georgetown University Medical Center, Washington DC, USA;
3SHARE Collaborative, Faculty of Medicine and Dentistry, Queen Mary University of London, London, UK; 4Community Resource Initiative, Boston, MA and Cambridge Health Alliance, Cambridge, MA, USA; 5Midway Immunology and Research Center, Fort Pierce, FL, USA; 6HIV/AIDS Unit, Division of Infectious Diseases, Geneva University Hospitals, Geneva, Switzerland; 7AIDS Clinical Center, NCGM, Tokyo, Japan; 8Infection and Immunity, Cardiff University, Cardiff, UK and Infectious Diseases, Cardiff and Vale University Health Board, Cardiff, UK; 9Merck & Co., Inc., Rahway, NJ, USA
|
| |
|
|
|
|
|
